IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

This is a multicenter, randomized, double-blind, phase II clinical study to evaluate the efficacy and safety of IN10018 in combination with PLD vs. placebo in combination with PLD in subjects with platinum-resistant recurrent ovarian cancer (including fallopian tube and primary peritoneal cancers).

Trial Details

NCT ID
NCT06014528
Phase
PHASE2
Sponsor
InxMed (Shanghai) Co., Ltd.
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • IN10018
  • Placebo of IN10018
  • Pegylated Liposomal Doxorubicin
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Ability to understand and willingness to sign informed consent(s). Signed informed consent must be obtained before any study specific procedures, e…
  • Female subjects ≥ 18 years at the time of signing informed consent.
  • Histologically confirmed epithelial ovarian cancer, fallopian tube cancer or primary peritoneum cancer and its subtype is high-grade serous carcino…
  • Have received platinum containing therapy and have radiological relapse or progression during platinum containing treatment or \< 6 months (184 cal…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →